Abstract:As a common characteristic of tumor cells, as well as of normal proliferating cells in the G1-phase of cell cycle, one finds constitutive high levels of all the glycolytic metabolites arising between glucose 6-phosphate and phosphoenolpyruvate. Thus, it is that the phosphometabolites fructose 1,6-bisphosphate, ribose 5-P, P-ribose-PP, NAD, GTP, CTO, UTP, UDP-glucose, glycerol 3-P, glycerol phosphocholine and glycerol phosphoethanolamine are useful in the 31P-nuclear magnetic resonance (NMR) detection of solid tumors in animals and man. This expansion of phosphometabolites is achieved during tumor formation as a result of reductions in levels of enzymes degrading phosphometabolites, owing to the decline in the glycerol 3-P hydrogen shuttle, and as a consequence of alterations in the glycolytic isoenzyme equipment. Tumor cells typically express a particular isoenzyme of pyruvate kinase called type M2 (K) at high levels. This isoenzyme is subject to a complex regulation by amino acids, by fructose 1,6-bisphosphate, and by hormonal- and oncogene-dependent phosphorylation. Pyruvate kinase type M2 is a substrate for the oncogene encoded PP60v-src-tyrosine kinase. A drastic decrease in the affinity for its substrate phosphoenolpyruvate found after transformation by the src-oncogene can be explained as a consequence of the phosphorylation of pyruvate kinase in serine and tyrosine. These phosphorylations induce the breakdown of tetrameric pyruvate kinase to the trimeric and dimeric forms. Unlike the tetrameric form, the dimeric form as a low affinity for phosphoenolpyruvate. Partial inactivation of pyruvate kinase and enolase on the one hand, and a hyperactivation of hexokinase and phosphofructokinase on the other hand, lead to an expansion of all metabolites. Only when these metabolites attain high levels, thereby assuring a sufficient supply of metabolites for RNA, DNA, lipid, and complex carbohydrate synthesis, can cell proliferation proceed. This accumulation of metabolites in the G1-phase cells has been termed a "metabolic budget system" because it senses not only the actual nutrient levels, but also the supply over a period of time. Monoclonal antibodies specific for the dimeric form of pyruvate kinase type M2 can be used for the immunohistological detection of tumor cells. The amount of the dimeric form in tumor cells closely correlates with the degree of malignancy and can be used for a nonspecific detection of tumors based on assays performed with patient's plasma.

The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation

Intracellular calcium regulates the tyrosine kinase receptor encoded by the MET oncogene

Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).

Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase.

Switching of the Substrate Specificity of Protein Tyrosine Phosphatase N12 by Cyclin‐dependent Kinase 2 Phosphorylation Orchestrating 2 Oncogenic Pathways

Oncogenic Activation of the Met Receptor Tyrosine Kinase Fusion Protein, Tpr–Met, Involves Exclusion from the Endocytic Degradative Pathway

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor.

Parallel phosphoproteomics and metabolomics map the global metabolic tyrosine phosphoproteome

The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy

Differential Responses of MET Activations to MET Kinase Inhibitor and Neutralizing Antibody.

The MET Family of Receptor Tyrosine Kinases Promotes a Shift to Pro-Tumor Metabolism

Pathogenesis Of Ron Receptor Tyrosine Kinase In Cancer Cells: Activation Mechanism, Functional Crosstalk, And Signaling Addiction

Aberrant RON and MET Co-overexpression As Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy

Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors

Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells

Molecular dynamics study of enhanced autophosphorylation by S904F mutation of the RET kinase domain

Pyruvate Kinase M2 Activates Mtorc1 by Phosphorylating AKT1S1.

Supplementary Figure 14 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Immunological detection of proteins phosphorylated at tyrosine in cells stimulated by growth factors or transformed by retroviral‐oncogene‐coded tyrosine kinases